EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieMultizentrische Studie

Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311

Theresa Tharakan iD, Sidharth V Puram iD, Randal C Paniello iD, Patrik Pipkorn iD, Paul Zolkind iD, Richard Alexander Harbison iD, Douglas Adkins, Peter Oppelt, Wade Thorstad, Hiram Gay, Anthony J Apicelli, Michael J Moravan and 4 more

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.1261 ↗

At a glance

Randomisierte kontrollierte Studie in Otolaryngology–Head and Neck Surgery, 2025. Written by Theresa Tharakan and 15 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA. Major MEDLINE topics: Oropharyngeal Neoplasms, Deglutition Disorders, Patient Reported Outcome Measures, Papillomavirus Infections. Cited 2 times so far (Crossref); 36 references. Funded by: NIDCD NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Evaluate the effect of deintensified postoperative adjuvant (chemo)radiation therapy (POA(C)RT) on patient‐reported dysphagia outcomes in patients with human papillomavirus (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Study Design Retrospective.

Setting

Multiple institutions, 2014 to 2021.

Methods

Patients with HPV+ OPSCC underwent transoral robotic surgery and reduced‐dose POA(C)RT by pathologic risk stratification. The Minimalist Trial (MINT) participants received 42 Gy radiation therapy (RT) with one dose of cisplatin 100 mg/m 2 (intermediate‐risk arm) or no cisplatin (low‐risk arm). The intermediate‐risk E3311 participants were randomized to 50 or 60 Gy RT. Analysis was per‐protocol by RT dose group. The primary outcome was change in MD Anderson Dysphagia Inventory (MDADI) composite score from baseline to 1‐year posttreatment, with a clinically meaningful decline (CMD) of ≥10 points.

Results

In total, 156 included patients received POA(C)RT: n = 28 at 42 to 49 Gy (n = 19 no cisplatin, n = 9 cisplatin), n = 82 at 50 to 59, and n = 46 at 60 Gy. Mean (SD) change in MDADI was −7.2 (10.6) in the 42 to 49 Gy group, −11.3 (17.2) in the 50 to 59 group, and −9.1 (15.1) in the 60 Gy group (analysis of variance [ANOVA] P = .46). The rate of CMD was 11/28 (39%) in the 42 to 49 Gy group, 43/82 (52%) in the 50 to 59 group, and 20/46 (44%) in the 60 Gy group (chi‐square P = .42). The rate of CMD was similar in those receiving 42 to 49 Gy with (3/9, 33%) and without cisplatin (8/19, 42%) (diff. 1%, 95% CI −29% to 47%). Gastrostomy tube rates were similar across dose groups.

Conclusion

Changes in dysphagia‐related quality‐of‐life (MDADI) from baseline to 1 year after POA(C)RT did not differ by radiation dose in the range of 42 to 60 Gy.

Subjects

MeSH terms (MEDLINE)

Oropharyngeal NeoplasmsDeglutition DisordersPatient Reported Outcome MeasuresPapillomavirus InfectionsChemoradiotherapyChemoradiotherapy, AdjuvantDeglutitionHumansMaleFemaleMiddle AgedRetrospective StudiesAgedCisplatinRobotic Surgical ProceduresRadiotherapy Dosage

Author keywords

HPV+ oropharyngeal squamous cell carcinomaadjuvant radiation dosedysphagiapatient‐reported outcomes

Substances

Cisplatin

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Genetics, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Pathology, Washington University School of Medicine, St Louis, Missouri, USA.

ORCID profiles: Theresa Tharakan, Sidharth V Puram, Randal C Paniello, Patrik Pipkorn, Paul Zolkind, Richard Alexander Harbison, Ryan S Jackson

Funding

  • NIDCD NIH HHS

Cite

APA

Tharakan, T., Puram, S. V., Paniello, R. C., Pipkorn, P., Zolkind, P., Harbison, R. A., Adkins, D., Oppelt, P., Thorstad, W., Gay, H., Apicelli, A. J., Moravan, M. J., Chernock, R., Mansour, M., Ley, J., & Jackson, R. S. (2025). Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1261

Vancouver

Tharakan T, Puram SV, Paniello RC, Pipkorn P, Zolkind P, Harbison RA, et al. Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1261

BibTeX
@article{Tharakan2025,
  author = {Tharakan, Theresa and Puram, Sidharth V and Paniello, Randal C and Pipkorn, Patrik and Zolkind, Paul and Harbison, Richard Alexander and Adkins, Douglas and Oppelt, Peter and Thorstad, Wade and Gay, Hiram and Apicelli, Anthony J and Moravan, Michael J and Chernock, Rebecca and Mansour, Mena and Ley, Jessica and Jackson, Ryan S},
  title = {Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.1261}
}
Start for free →